Debates rekindled on government's stern measures on generic data fabrication

The controversy over the bioequivalence data fabrication has flared again following the government's unilateral administrative measure to cancel the licenses of generic drugs without lawful procedures.

In response to such harsh measures, the generic markers, including Hyundai Pharm and Hanmi Pharm, filed a lawsuit for an injunction to bar the Korea Food and Drug Administration from canceling...